Voyager Therapeutics has appointed Robert Pietrusko as its senior vice president of regulatory affairs.
Pietrusko most recently served as vice president of global regulatory affairs and quality at ViroPharma prior to its acquisition by Shire. Before that, he was senior vice president of worldwide regulatory affairs at Millennium Pharmaceuticals.
Alnylam Pharmaceuticals has elected Amy Schulman to its board of directors.
Schulman is the former executive vice president and general counsel of Pfizer, where she also was the business unit lead for its consumer healthcare business. She currently is a senior lecturer at Harvard Business School.
Frank Slack has been appointed as the director of the Beth Israel Deaconess Medical Center's Institute for RNA Medicine, which was launched this month to foster research into the use of RNA to treat cancer and other diseases.
Slack was previously at Yale University, where he conducted key microRNA research.